PD 161570


Related Categories Approved Therapeutics / Drug Candidates, Bioactive Small Molecules Alphabetical Index, Bioactive Small Molecules, Cell Biology, Cell Signaling, and Neuroscience,

Quality level: 100

Assay: ≥98% (HPLC)

Form: dust

mfr. No:  Pfizer®

Color: white to off-white


DMSO :> 10 mg / mL

Creator: Pfizer



5, 25 mg in a glass bottle

Biochemical / Physiological Actions

PD-161570 is a human FGF-1 receptor tyrosine kinase inhibitor.

Features and Benefits

  • This compound is a featured product for phosphatase kinase biology research. Click here to discover more featured phosphatase kinase biology products. Learn more about bioactive small molecules for other research areas at sigma.com/discover-bsm.
  • This compound is also offered as part of Sigma’s Library of Pharmacologically Active Compounds (LOPAC®Pfizer), a collection of 90 drugs and research tools developed by Pfizer. Click here to find out more.
  • This compound is listed on the FGFR page of the Signal Transduction and Receptor Classification Manual. To browse other pages in the manual, click here.

Read more About: Nasopharyngeal Panbio COVID-19 Antigen Performed at Point-of-Care Has a High Sensitivity in Symptomatic and Asymptomatic Patients With Higher Risk for Transmission and Older Age.

Other notes

This compound was developed by Pfizer for phosphatase kinase biology research. To learn more about Sigma’s partnership with Pfizer and to view other high-quality, authentic Pfizer compounds, visit sigma.com/bsm-pfizer. To browse the list of other pharmaceutical industry-developed compounds and approved drugs/drug candidates, click here.

Legal information

  • It is sold for research purposes under the agreement of Pfizer Inc.
  • LOPAC is a registered trademark of Sigma-Aldrich Co. LLC
  • Pfizer is a registered trademark of Pfizer, Inc.

Leave a Reply

Your email address will not be published. Required fields are marked *

Blog PCR

Human monkeypox – After 40 years, an unintended consequence of smallpox eradication

Smallpox eradication, coordinated by the WHO and certified 40 years ago, led to the cessation of routine smallpox vaccination in most countries. It is estimated that over 70% of the world’s population is no longer protected against smallpox, and through cross-immunity, to closely related orthopox viruses such as monkeypox. Monkeypox is now a re-emerging disease. […]

Read More
Blog parg antibody

A Tale of Two Viruses: Coinfections of Monkeypox and Varicella Zoster Virus in the Democratic Republic of Congo

Recent enhanced monkeypox (MPX) surveillance in the Democratic Republic of Congo, where MPX is endemic, has uncovered multiple cases of MPX and varicella zoster virus (VZV) coinfections. The purpose of this study was to verify if coinfections occur and to characterize the clinical nature of these cases. Clinical, epidemiological, and laboratory results were used to […]

Read More